JP2005517412A5 - - Google Patents

Download PDF

Info

Publication number
JP2005517412A5
JP2005517412A5 JP2003568094A JP2003568094A JP2005517412A5 JP 2005517412 A5 JP2005517412 A5 JP 2005517412A5 JP 2003568094 A JP2003568094 A JP 2003568094A JP 2003568094 A JP2003568094 A JP 2003568094A JP 2005517412 A5 JP2005517412 A5 JP 2005517412A5
Authority
JP
Japan
Prior art keywords
antibody
antisense oligonucleotide
nephropathy
activity
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003568094A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005517412A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/004186 external-priority patent/WO2003068983A1/en
Publication of JP2005517412A publication Critical patent/JP2005517412A/ja
Publication of JP2005517412A5 publication Critical patent/JP2005517412A5/ja
Pending legal-status Critical Current

Links

JP2003568094A 2002-02-12 2003-02-12 腎疾患の診断及び治療のためのＡｘｌ受容体の使用 Pending JP2005517412A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35637402P 2002-02-12 2002-02-12
PCT/US2003/004186 WO2003068983A1 (en) 2002-02-12 2003-02-12 Use of the axl receptor for diagnosis and treatment of renal disease

Publications (2)

Publication Number Publication Date
JP2005517412A JP2005517412A (ja) 2005-06-16
JP2005517412A5 true JP2005517412A5 (OSRAM) 2006-04-13

Family

ID=27734638

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003568094A Pending JP2005517412A (ja) 2002-02-12 2003-02-12 腎疾患の診断及び治療のためのＡｘｌ受容体の使用

Country Status (7)

Country Link
US (3) US20030157573A1 (OSRAM)
EP (1) EP1483400A4 (OSRAM)
JP (1) JP2005517412A (OSRAM)
CN (1) CN1646695A (OSRAM)
AU (1) AU2003223172A1 (OSRAM)
IL (1) IL163547A0 (OSRAM)
WO (1) WO2003068983A1 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1483400A4 (en) * 2002-02-12 2007-07-11 Quark Biotech Inc USE OF THE AXL RECEPTOR FOR THE DIAGNOSIS AND TREATMENT OF A KIDNEY DISEASE
AU2003286746A1 (en) * 2002-10-29 2004-05-25 Rigel Pharmaceuticals, Inc. Modulators of angiogenesis and tumorigenesis
US8038996B2 (en) 2004-03-27 2011-10-18 University Of Arizona Composition and method for cancer treatment
TW200726845A (en) * 2006-01-02 2007-07-16 Nat Defense Medical Ct Biomarker molecular of renal illness and detecting method for the same
JP2010514810A (ja) 2006-12-29 2010-05-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌインヒビターとして有用な置換トリアゾール
WO2009005813A1 (en) * 2007-07-02 2009-01-08 Wyeth Modulators of axl for use in treating bone disorders
US9074192B2 (en) 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
PT3241840T (pt) 2010-01-22 2022-10-13 Univ Leland Stanford Junior Inibição da sinalização de axl em terapêutica anti-metastática
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
MY165215A (en) 2012-01-31 2018-03-09 Daiichi Sankyo Co Ltd Pyridone derivatives
EP2626705A1 (en) * 2012-02-13 2013-08-14 Institut d'Investigacions Biomédiques August Pi i Sunyer Use of the soluble form of AXL in the diagnosis and/or prognosis of heart failure syndrome
EP3076966A2 (en) * 2013-12-02 2016-10-12 BerGenBio AS Use of kinase inhibitors
US10137173B2 (en) 2014-10-20 2018-11-27 Aravive Biologics, Inc. Antiviral activity of Gas6 inhibitor
KR102431003B1 (ko) * 2014-10-20 2022-08-09 아스튜트 메디컬 인코포레이티드 신손상 및 신부전의 진단 및 예후를 위한 방법 및 조성물
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MX2019008260A (es) 2017-01-12 2020-01-27 Astute Medical Inc Metodos y composiciones para la evaluacion y tratamiento de lesion renal e insuficiencia renal con base en la medicion del ligando 14 de quimiocina de la porcion c-c.
CN110536703B (zh) 2017-04-20 2024-07-12 Adc治疗有限公司 使用抗axl抗体-药物缀合物的组合疗法
CN113215157B (zh) * 2021-05-20 2022-06-21 徐州医科大学 特异性靶向人AXL基因的sgRNA及其应用
CN113252911B (zh) * 2021-07-02 2021-12-10 珠海丽珠试剂股份有限公司 SARS-CoV-2中和抗体的检测试剂盒及其应用
KR102763266B1 (ko) * 2021-11-30 2025-02-04 충남대학교산학협력단 Axl을 포함하는 지방간 예방 또는 치료용 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468634A (en) * 1991-06-24 1995-11-21 The University Of North Carolina At Chapel Hill Axl oncogene
AU697142B2 (en) * 1993-11-23 1998-10-01 Genentech Inc. Protein tyrosine kinases named Rse
CA2179383A1 (en) * 1994-01-14 1995-07-20 Ira D. Goldfine Antagonists to insulin receptor tyrosine kinase inhibitor
US5538861A (en) * 1994-07-29 1996-07-23 Amgen Inc. DNA encoding a stimulating factor for the axl receptor
US6211142B1 (en) * 1995-03-10 2001-04-03 Genentech, Inc. Compositions comprising gas6 polypeptides and articles of manufacture comprising the same
US5849585A (en) * 1995-05-10 1998-12-15 Genetech, Inc. Isolating and culturing Schwann cells
US20040102389A1 (en) * 1995-10-26 2004-05-27 Ribozyme Pharmaceuticals, Inc. Nucleic acid-mediated treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
US6235769B1 (en) * 1997-07-03 2001-05-22 Sugen, Inc. Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
US6236769B1 (en) * 1998-01-28 2001-05-22 Cognex Corporation Machine vision systems and methods for morphological transformation of an image with zero or other uniform offsets
US20030149113A1 (en) * 2001-10-12 2003-08-07 Caplan Michael J. Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease
KR100872437B1 (ko) * 2000-12-01 2008-12-05 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US20020165158A1 (en) * 2001-03-27 2002-11-07 King George L. Methods of modulating angiogenesis
AU2002368202B2 (en) * 2001-11-02 2008-06-05 Insert Therapeutics, Inc Methods and compositions for therapeutic use of RNA interference
EP1483400A4 (en) * 2002-02-12 2007-07-11 Quark Biotech Inc USE OF THE AXL RECEPTOR FOR THE DIAGNOSIS AND TREATMENT OF A KIDNEY DISEASE
US20030229906A1 (en) * 2002-04-15 2003-12-11 Gelman Irwin H. Methods and compositions for the treatment of disorders of HIV infection
ATE477337T1 (de) * 2003-01-16 2010-08-15 Univ Pennsylvania Zusammensetzungen und verfahren zur sirna-hemmung von icam-1

Similar Documents

Publication Publication Date Title
JP2023058575A5 (OSRAM)
JP2014511686A5 (OSRAM)
JP2017536119A5 (OSRAM)
JP2012050438A5 (OSRAM)
JP2023519140A5 (OSRAM)
JP2010533171A5 (OSRAM)
JP2009506124A5 (OSRAM)
JP2009511034A5 (OSRAM)
JP2010526153A5 (OSRAM)
JP2005517430A5 (OSRAM)
WO2007134014A3 (en) Compounds and methods for modulating expression of gcgr
JP2008513513A5 (OSRAM)
JP2012505657A5 (OSRAM)
JP2005500025A5 (OSRAM)
EP1799859A4 (en) IMPROVED ANTISENSE OLIGONUCLEOTIDE
WO2008008433A3 (en) Substituted acylanilides and methods of use thereof
JP2012105686A5 (OSRAM)
JP2009544281A5 (OSRAM)
EP2062586A3 (en) Use of low doses of oligonucleotides antisense to tgf-beta, vegf, interleukin-10, c-jun, c-fos or prostaglandin e2 genes in the treatment of tumors
JP2022537987A5 (OSRAM)
IL262728B1 (en) Oligonucleotides conjugated to the ligand complex of the glp-1 receptor and their uses
JP2007517498A5 (OSRAM)
JP2006510659A5 (OSRAM)
EP1185696A4 (en) MODIFICATION OF THE EXPRESSION OF THE HUMAN PROTEIN KINASE C-DELTA WITH THE HELP OF ANTISENSE OLIGONUCLEOTIDS
WO2002103014A3 (fr) Oligonucleotides antisens capables d'inhiber la formation des tubes capillaires